Analysis Palivizumab and the importance of cost effectiveness BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b1935 (Published 11 June 2009) Cite this as: BMJ 2009;338:b1935 Article Related content Metrics Responses Peer review Related articles Letter An example of indication creep Published: 06 July 2009; BMJ 339 doi:10.1136/bmj.b2724 See more Communicating risk to patients in the emergency department BMJ December 05, 2016, 355 i6437; DOI: https://doi.org/10.1136/bmj.i6437 Biological treatment is approved for severe eosinophilic asthma BMJ December 01, 2016, 355 i6472; DOI: https://doi.org/10.1136/bmj.i6472 Patient care is at risk from lack of new funds in autumn statement, healthcare leaders warn BMJ November 24, 2016, 355 i6356; DOI: https://doi.org/10.1136/bmj.i6356 Government must be clearer in its claims about NHS funding, says statistics watchdog BMJ November 24, 2016, 355 i6340; DOI: https://doi.org/10.1136/bmj.i6340 US must address addiction as an illness, not as a moral failing, Surgeon General says BMJ November 22, 2016, 355 i6265; DOI: https://doi.org/10.1136/bmj.i6265 Cited by... An example of indication creepFulltext
